Is Retatrutide FDA Approved?
Last updated September 26, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced
← Back to the Retatrutide Hub · See also: Dosage · vs Tirzepatide
No. Retatrutide is not FDA approved as of September 26, 2026 — and not approved by the EMA or any other regulator. It is an investigational drug (Eli Lilly's TRIUMPH program) and cannot be lawfully prescribed or sold as a medicine. The lawful routes are a clinical trial or, for a narrow group of patients, Lilly's pre-approval expanded-access program (NCT07629401).
Lilly plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027 (Lilly, July 23, 2026). Under FDA's review goals for a new biologic, a decision comes about 12 months after submission on a standard review, or about 8 months with priority review, so the earliest plausible approval is late 2027 and a standard review lands in early 2028. Neither date is set, and timelines slip. Treat any specific "release date" online as speculation.
Where it is in development
Retatrutide is being tested in the TRIUMPH Phase 3 program, which spans more than 5,800 participants across obesity, type 2 diabetes, knee osteoarthritis, obstructive sleep apnea, chronic low-back pain, fatty-liver disease, and cardio-renal outcomes. The first readout, TRIUMPH-4, reported in December 2025; a Phase 3 diabetes readout (TRANSCEND-T2D-1) followed in March 2026. TRIUMPH-1 (obesity) followed on May 21, 2026, and TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (established cardiovascular disease) on July 23, 2026, all meeting their primary endpoints. Lilly counts five positive Phase 3 trials and says it now has the clinical package for obesity, knee osteoarthritis pain and obstructive sleep apnea. What it is still finishing is the chemistry, manufacturing and controls (CMC) part of the application, the evidence that it can make the drug consistently at scale. The application will be a Biologics License Application, not a New Drug Application (Lilly, July 23, 2026). Lilly had earlier pointed to a filing as soon as 2026 (CNBC, July 23, 2026).
Realistic timeline
| Stage | Status / expectation |
|---|---|
| Phase 2 (obesity, T2D, MASLD) | ✅ Complete, published 2023–2024 |
| TRIUMPH-4 — first Phase 3 readout | ✅ Topline Dec 2025 (28.7% weight loss) |
| TRANSCEND-T2D-1 — Phase 3 diabetes | ✅ Topline March 2026 |
| TRIUMPH-1, -2 and -3 | ✅ Topline May 21 and July 23, 2026 |
| Pre-approval expanded access (NCT07629401) | ✅ Available since June 2026, narrow criteria |
| FDA submission (BLA) | ⏳ Planned for Q1 2027 (Lilly, July 23, 2026) |
| FDA review | ⏳ Typically ~10 months after filing |
| Possible approval decision | ⏳ Late 2027 at the earliest (priority review); early 2028 on a standard review. Not confirmed |
What still has to happen
Three things, as of September 26, 2026: (1) Lilly has to finish the CMC package; (2) it has to file the BLA, planned for Q1 2027; and (3) the FDA has to accept and review it. The clinical side is largely done: five positive Phase 3 trials, with dysesthesia now reported in TRIUMPH-2 and TRIUMPH-3 as well as TRIUMPH-4, and a cardiovascular-events analysis in TRIUMPH-3 that was inconclusive (hazard ratio 0.82 for MACE-5, 95% CI 0.55 to 1.22). A request for more data or a manufacturing question could still push the timeline back.
Context: how fast this can move
Approvals in this category can move quickly when the FDA prioritizes them. Lilly's oral GLP-1 pill orforglipron (Foundayo) became the fastest new-molecular-entity approval since 2002 — read our news coverage of the orforglipron approval. That doesn't guarantee a fast path for retatrutide (a different molecule with a larger, more complex program and a fresh safety signal), but it shows the regulatory environment is receptive to high-impact obesity drugs.
Until then — access & legality
Because it is not approved, retatrutide cannot be prescribed for weight loss, and because it is not a component of any FDA-approved drug and is not on the 503A bulks list, compounding pharmacies are not a lawful route either. The lawful routes are a clinical trial, where it's provided under supervision at no cost, or Lilly's pre-approval expanded-access program for adults with severe obesity and serious complications who cannot join a trial (NCT07629401, available since June 2026; read September 26, 2026). Products sold online as "research chemicals" are unregulated, of unverified identity and purity, and fall outside any approved medical framework. For the broader rules, see Are Peptides Legal? and the full cost & access section on the hub.
Frequently asked questions
Is retatrutide approved anywhere in the world?
No. As of September 26, 2026 it has no regulatory approval in any country; it is investigational everywhere.
What's the earliest it could be approved?
Late 2027, if Lilly files in Q1 2027 as planned and FDA grants priority review (about 8 months). A standard review (about 12 months) would put a decision in early 2028. Nothing is confirmed (as of September 26, 2026).
Will it be approved for diabetes too, or just obesity?
The program covers both, plus other conditions. Which indications appear on an eventual label depends on which trials succeed; obesity and type 2 diabetes are the lead indications.
Does a clinical-trial readout mean it's approved?
No. Positive topline results are a milestone toward approval, not approval itself. The FDA reviews the complete package before any decision.
Sources
- Eli Lilly & Company. TRIUMPH-4 Phase 3 topline results. News release, December 11, 2025.
- Eli Lilly & Company. TRANSCEND-T2D-1 Phase 3 topline. Company communication, March 2026.
- ClinicalTrials.gov — TRIUMPH program registrations (e.g., NCT05882045).
- U.S. FDA. Bulks-list determinations affecting peptide compounding (503A/503B), 2023–2026.
- Eli Lilly & Company. TRIUMPH-1 Phase 3 topline results (obesity, 80 weeks). News release, May 21, 2026.
- Eli Lilly & Company. TRIUMPH-2 and TRIUMPH-3 Phase 3 topline results; Biologics License Application planned for Q1 2027. News release, July 23, 2026.
- CNBC. Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials. July 23, 2026.
- ClinicalTrials.gov. NCT07629401, Pre-approval Expanded Access of Retatrutide (LY3437943). Eli Lilly and Company. First posted June 5, 2026; last updated August 6, 2026; read September 26, 2026.
- US Food and Drug Administration. PDUFA VII performance goals, fiscal years 2023–2027: original BLAs are reviewed within 10 months of the 60-day filing date (6 months for priority review).
Medical disclaimer: Education only, not medical advice. Retatrutide is investigational and not approved for use. Consult a licensed clinician.